Glycemic Control and Complications in Type 2 Diabetes Mellitus

American Journal of Medicine

Volumn 123, Issue 3 SUPPL., 2010, Pages

  Stolar, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetic complications; Glycemic control; Hyperglycemia; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; STANDARD; VASCULAR DISEASE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 77449089099     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.12.004     Document Type: Article

References (56)

1. Centers for Disease Control and Prevention. Centers for Disease Control National Diabetes Fact Sheet. General information and national estimates on diabetes in the United States (2007), Centers for Disease Control and Prevention, US Dept of Health and Human Services, Atlanta, GA
2. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
3. Nichols G.A., Hillier T.A., and Brown J.B. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 30 (2006) 228-233
4. de Vegt F., Dekker J.M., Jager A., et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 285 (2001) 2109-2113
5. Garber A.J., Handelsman Y., Einhorn D., et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin?. A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 14 (2008) 933-946
6. Tapp R.J., Shaw J.E., Zimmet P.Z., et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 44 (2004) 792-798
7. American Diabetes Association. Executive summary: standards of medical care in diabetes-2009. Diabetes Care 32 suppl 1 (2009) S13-S61
8. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 suppl 1 (2007) 3-68
9. Koro C.E., Bowlin S.J., Bourgeois N., and Fedder D.O. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care 27 (2004) 17-20
10. Ong K.L., Cheung B.M., and Wong L.Y. Prevalence, treatment, and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 18 (2008) 222-229
11. Morgan C.L., Currie C.J., and Peters J.R. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care 23 (2000) 1103-1107
12. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
13. Gilmer T.P., O'Connor P.J., Rush W.A., et al. Predictors of health care costs in adults with diabetes. Diabetes Care 28 (2005) 59-64
14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
16. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1946 and 1973. Diabetes Care 1 (1978) 168-188
17. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
18. Skyler J.S. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am 25 (1996) 243-254
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
20. Heilig C.W., Concepcion L.A., Riser B.L., Freytag S.O., Zhu M., and Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96 (1995) 1802-1814
21. Kaiser N., Sasson S., Feener E.P., et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42 (1993) 80-89
22. Engerman R.L., Kern T.S., and Larson M.E. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 37 (1994) 141-144
23. Pang Y., Hunton D.L., Bounelis P., and Marchase R.B. Hyperglycemia inhibits calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 51 (2002) 3461-3467
24. UK Prospective Diabetes Study (UKPDS) Group. UKPDS 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
25. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., and Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31 (2008) 464-469
26. 1C. Diabetes Care 26 (2003) 881-885
27. Krakoff J., Hanson R.L., Kobes S., and Knowler W.C. Comparison of the effect of plasma glucose concentrations on microvascular disease between Pima Indian youths and adults. Diabetes Care 24 (2001) 1023-1028
28. Kuusisto J., Mykkänen L., Pyörälä K., and Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43 (1994) 960-967
29. Khaw K.T., Wareham N., Luben R., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322 (2001) 15-18
30. Ducimetiere P., Eschwege E., Papoz L., Richard J.L., Claude J.R., and Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19 (1980) 205-210
31. Eschwege E., Richard J.L., Thibult N., et al. Coronary heart disease mortality in relation with diabetes, blood glucose, and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl 15 (1985) 41-46
32. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2 (1979) 131-141
33. Stolar M.W. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 37 suppl 1 (1988) 1-9
34. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care 22 (1999) 233-240
35. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., and Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002) 1129-1134
36. Norhammar A., Tenerz A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
37. Kosiborod M., Inzucchi S.E., Krumholz H.M., et al. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med 169 (2009) 438-446
38. Hillier T.A., and Pedula K.L. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 26 (2003) 2999-3005
39. Hillier T.A., and Pedula K.L. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 24 (2001) 1522-1527
40. Purushothaman K.R., Meerarani P., and Moreno P.R. Inflammation and neovascularization in diabetic atherosclerosis. Indian J Exp Biol 45 (2007) 93-102
41. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
42. Purushothaman K.R., Fuster V., Sirol M., et al. Diabetic plaque inflammation and neovascularization are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. Presented at the American College of Cardiology's 55th Annual Scientific Session i2 Summit 2006; March 11-14, 2006; Atlanta, GA. J Am Coll Cardiol 47 suppl A (2006) 295A Abstract 912-193
43. Stettler C., Allemann S., Juni P., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152 (2006) 27-38
44. Esposito K., Giugliano D., Nappo F., Marfella R., and Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 (2004) 214-219
45. Gerstein H.C., Miller M.E., Byington R.P., et al., ACCORD (Action to Control Cardiovascular Risk in Diabetes) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
46. Patel A., MacMahon S., Chalmers J., et al., ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
47. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
48. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009) 187-192
49. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
50. Buchanan T.A. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 25 suppl B (2003) B32-B46
51. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88 (2004) 787-835
52. Kahn S.E. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 4047-4058 Clinical review 135
53. Lebovitz H.E. Insulin secretagogues: old and new. Diabetes Rev 7 (1999) 139-153
54. Del Prato S., Wishner W.J., Gromada J., and Schluchter B.J. β-Cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 6 (2004) 319-331
55. Weir G.C., Laybutt D.R., Kaneto H., Bonner-Weir S., and Sharma A. β-Cell adaptation and decompensation during the progression of diabetes. Diabetes 50 suppl 1 (2001) S154-S159
56. Garvey W.T., Olefsky J.M., Griffin J., Hamman R.F., and Kolterman O.G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34 (1985) 222-234